CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? Association of Cardiovascular Disease With Respiratory Disease Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
|<<... 9 10 11 12 13 14 15 ...>>|

Clinical Trial2014 Sep 11;371(11):993-1004.

JOURNAL：N Engl J Med. Article Link

Angiotensin–neprilysin inhibition versus enalapril in heart failure

McMurray JJ, Packer M, PARADIGM-HF Investigators and Committees. Keywords: angiotensin receptor-neprilysin inhibitor LCZ696; enalapril; HFrEF; mortality; survival; hospitalization for heart failure

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top